-
Program Alert
Novavax Coverage
-
Novavax COVID vaccine trial participants left battling a tough decision after FDA submission delayed
Novavax recently announced that it would delay its timeline for seeking U.S. authorization for its two-dose COVID-19 vaccine. This leaves thousands of Novavax trial participants stranded when it comes to travel, events and even jobs, because they can't get a different, approved vaccine. -
Novavax trial participants stuck as more restrictions placed on the unvaccinated
Novavax is looking for more unvaccinated people to participate in trials testing the effectiveness of vaccines and boosters. But those trial participants are running into roadblocks in everyday life. -
Novavax study: COVID-19 vaccine about 90% effective
Novavax, which developed a COVID-19 vaccine that is being manufactured by FUJIFILM Diosynth Biotechnologies, in a Morrisville facility, has announced the vaccine is about 90% effective overall. -
UNC recruiting kids for Novavax vaccine trial in big step toward herd immunity
As the wait for federal approval to to start vaccinating children against COVID-19 continues, researchers at UNC Health are wasting no time with the Novavax vaccine. -
UNC recruiting children for Novavax COVID-19 trial
Novavax is looking for children between the ages of 12 and 17 for its COVID-19 vaccine trial at UNC. -
New COVID-19 vaccines are on the way; what this means for getting the public vaccinated
UNC Infectious Disease Expert Dr. Cynthia Gay says the more vaccines we can get, the better.